HDAC6 and neurodegenerative disease: In this context, mercaptoacetamides are growing as a potential alternative for the selective inhibition of HDAC6, since they do not present the same risk of mutagenicity, which is of particular interest in the case of long-term treatments, such as in neurodegenerative diseases, as well as having suitable physicochemical properties with regard to the permeability parameter of the blood–brain barrier [24,110].